EPCORE™FL-2Active, not recruiting

Epcoritamab (a new bispecific antibody) in combination with rituximab and lenalidomide as first-line therapy for follicular lymphoma

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
First line
Phase
Phase III

What is this trial about?

(FL) is a malignant disease of the . The standard treatment usually consists of immunochemotherapy. , an antibody that targets cancer cells while simultaneously stimulating the immune system (bispecific), is already approved for use in other types of . The EPCORE FL-2 study is investigating the safety and efficacy of epcoritamab in combination with and (R²) as for FL. Patients aged 18 and older with untreated FL are eligible to participate in the study.

Detailed description

Follicular lymphoma (FL) is a type of (NHL) in which malignant accumulate in the lymph nodes. are a type of white blood cell that is part of the immune system. The cause of FL is not fully understood, but genetic and immune system disorders play a role. This disease is chronic and generally incurable with available standard therapies, but it can often be effectively controlled for a long time. Treatment is tailored to the symptoms and physical condition of the affected patients. Patients with early-stage (limited) FL usually receive radiation therapy. The standard treatment for advanced-stage FL involves a combination of chemotherapy and . In cases of relapse or a form of FL, one treatment option is the combination of lenalidomide with rituximab (R²). The combination of the epcoritamab with R² could represent another treatment option for follicular lymphoma. Epcoritamab is a that targets cancer cells while simultaneously stimulating the immune system; it is already approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

The EPCORE™FL-2 study (Phase 3 trial) is investigating the efficacy and safety of epcoritamab in combination with R² compared to various standard therapies. Patients are randomly assigned to five groups as part of the study. This study is examining five different treatment groups to determine which therapy is the most effective and best tolerated for previously untreated follicular lymphoma. One group receives the new combination of epcoritamab, rituximab, and lenalidomide—which is designed to strongly activate the immune system against cancer cells. Two other groups receive established standard therapies with chemotherapy: either rituximab or combined with CHOP or . Another group receives only rituximab and lenalidomide without epcoritamab—a standard chemotherapy-free treatment. The final group receives a personalized selected by the physician, depending on what is most suitable for the patient. The goal is to directly compare the different treatment approaches to identify the best treatment option for patients with this disease. The study is open-label, meaning that both the medical staff and the patient know which medications are being administered. Treatment lasts 120 weeks, and examinations as part of the study will continue for up to 10 years, during which the effectiveness of the therapy and the occurrence of side effects from the various medications will be evaluated. The key factors are whether the disease responds completely to the therapy and how long the disease-free survival rate is after treatment.

Men and women aged 18 and older with untreated stage 2–4 follicular lymphoma are eligible to participate in this study.

Facts

  1. Disease: (FL).
  2. Cancer characteristics: Untreated, stage 2–4.
  3. What the study investigates: Evaluation of the efficacy and side effects of in combination with and (R²) compared to immunochemotherapy as .
  4. Study objective: To determine whether the new combination therapy achieves a higher response rate and disease-free survival rate compared to .
  5. Study duration: 120 weeks. for up to 10 years.
  6. Study characteristics: Phase 3 study, , open-label.

Trial sites

7 trial sites in Germany are listed. Find a site near you.

  • St.-Antonius-Hospital gGmbH Eschweiler

    Dechant-Deckers-Strasse 8, 52249 Eschweiler

    Status unknown
  • Universitätsklinikum Frankfurt

    Theodor-Stern-Kai 7, 60590 Frankfurt am Main

    Active, not recruiting
  • Städtisches Klinikum Karlsruhe gGmbH

    Moltkestrasse 90, 76133 Karlsruhe

    Status unknown
  • Klinikum Kassel

    Moenchebergstrasse 41-43, 34125 Kassel

    Status unknown
  • Klinikum der Stadt Ludwigshafen am Rhein gGmbH

    Bremserstrasse 79, 67063 Ludwigshafen am Rhein

    Status unknown
  • Otto-von-Guericke-Universität Magdeburg

    Leipziger Strasse 44, 39120 Magdeburg

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.